These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 19344191)

  • 1. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial.
    Lubenau H; Bias P; Maly AK; Siegler KE; Mehltretter K
    BioDrugs; 2009; 23(1):43-51. PubMed ID: 19344191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of two recombinant granulocyte colony-stimulating factor products after subcutaneous injection in healthy volunteers.
    Lubenau H; Sveikata A; Gumbrevicius G; Macijauskiene J; Fokas V; Kazlauskas S; Janulionis V
    Int J Clin Pharmacol Ther; 2009 Apr; 47(4):275-82. PubMed ID: 19356394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
    Gatzemeier U; Ciuleanu T; Dediu M; Ganea-Motan E; Lubenau H; Del Giglio A
    J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative pharmacokinetic and pharmacodynamic study of FSK0808 versus reference filgrastim after repeated subcutaneous administration in healthy Japanese men.
    Matsuguma K; Matsuki S; Sakamoto K; Shiramoto M; Nakagawa M; Kimura M; Irie S; Kaneko D; Ohnishi A
    Clin Pharmacol Drug Dev; 2015 Mar; 4(2):99-104. PubMed ID: 27128214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen®.
    Crobu D; Spinetti G; Schrepfer R; Tonon G; Jotti GS; Onali P; Dedoni S; Orsini G; Di Stefano A
    BMC Pharmacol Toxicol; 2014 Feb; 15():7. PubMed ID: 24555723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
    Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the pharmacokinetic and pharmacodynamic properties of two recombinant granulocyte colony-stimulating factor formulations after single subcutaneous administration to healthy volunteers.
    Sveikata A; Gumbrevičius G; Seštakauskas K; Kregždytė R; Janulionis V; Fokas V
    Medicina (Kaunas); 2014; 50(3):144-9. PubMed ID: 25323541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy.
    Johnston E; Crawford J; Blackwell S; Bjurstrom T; Lockbaum P; Roskos L; Yang BB; Gardner S; Miller-Messana MA; Shoemaker D; Garst J; Schwab G
    J Clin Oncol; 2000 Jul; 18(13):2522-8. PubMed ID: 10893282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
    Waller CF; Bronchud M; Mair S; Challand R
    Ann Hematol; 2010 Oct; 89(10):971-8. PubMed ID: 20567823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim.
    van Der Auwera P; Platzer E; Xu ZX; Schulz R; Feugeas O; Capdeville R; Edwards DJ
    Am J Hematol; 2001 Apr; 66(4):245-51. PubMed ID: 11279634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen
    Yao HM; Ottery FD; Borema T; Harris S; Levy J; May TB; Moosavi S; Zhang J; Summers M
    BioDrugs; 2019 Apr; 33(2):207-220. PubMed ID: 30900158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
    Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial.
    Waller CF; Bronchud M; Mair S; Challand R
    Ann Hematol; 2010 Sep; 89(9):927-33. PubMed ID: 20428872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A glycosylated recombinant human granulocyte colony stimulating factor produced in a novel protein production system (AVI-014) in healthy subjects: a first-in human, single dose, controlled study.
    Varki R; Pequignot E; Leavitt MC; Ferber A; Kraft WK
    BMC Clin Pharmacol; 2009 Jan; 9():2. PubMed ID: 19175929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of FSK0808 and Gran after single intravenous drip administration or single subcutaneous administration: comparative study in healthy Japanese adult male subjects.
    Matsuguma K; Matsuki S; Eunhee C; Watanabe A; Tanaka A; Sakamoto K; Takeshita H; Hitaka A; Shigetome K; Kimura M; Miyamoto A; Irie S; Kaneko D; Ohnishi A
    Drug Dev Ind Pharm; 2015 Mar; 41(3):470-5. PubMed ID: 24471477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant filgrastim (BK0023) pharmacodynamics and pharmacokinetics after single and multiple escalating doses in an equivalence study in healthy men.
    Di Stefano AF; Spinetti G; Rusca A; Radicioni MM; Loprete L; Lamparelli DM; Michael Hepp J; Crobu D; Schrepfer R; Tonon G
    Clin Drug Investig; 2015 Sep; 35(9):533-45. PubMed ID: 26251016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers.
    Hernández-Bernal F; García-García I; González-Delgado CA; Valenzuela-Silva C; Soto-Hernández R; Ducongé J; Cervantes-Llano M; Blanco-Garcés E; Rodríguez V; García-Vega Y; Bello-Rivero I; Olivera-Ruano L; López-Saura P
    Biopharm Drug Dispos; 2005 May; 26(4):151-9. PubMed ID: 15799006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy.
    Engert A; Griskevicius L; Zyuzgin Y; Lubenau H; del Giglio A
    Leuk Lymphoma; 2009 Mar; 50(3):374-9. PubMed ID: 19347726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between absolute neutrophil count profiles and pharmacokinetics of DA-3031, a pegylated granulocyte colony-stimulating factor (pegylated-G-CSF): a dose block-randomized, double-blind, dose-escalation study in healthy subjects.
    Ahn LY; Shin KH; Lim KS; Kim TE; Jeon H; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Drug Investig; 2013 Nov; 33(11):817-24. PubMed ID: 24078278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.